New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins

  • Authors:
    • Tomohiro Kagawa
    • Ayuka Mineda
    • Tomotaka Nakagawa
    • Ayaka Shinohara
    • Ryosuke Arakaki
    • Hiroaki Inui
    • Hiroki Noguchi
    • Atsuko Yoshida
    • Riyo Kinouchi
    • Yuri Yamamoto
    • Kanako Yoshida
    • Takashi Kaji
    • Masato Nishimura
    • Takeshi Iwasa
  • View Affiliations

  • Published online on: March 26, 2024     https://doi.org/10.3892/etm.2024.12520
  • Article Number: 231
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Secreted frizzled‑related proteins (SFRPs) are involved in the development of various types of cancer and function by suppressing the Wnt signaling pathway. To elucidate the clinical implications of SFRPs in uterine sarcoma, SFRP expression levels and their effects on uterine leiomyosarcoma cells were examined. Immunostaining for SFRP4 was performed on uterine smooth muscle, uterine fibroid and uterine leiomyosarcoma tissues. Additionally, the effects of SFRP4 administration on cell viability, migration and adhesion were evaluated in uterine leiomyosarcoma SKN cells using the WST‑1 assay (Roche Diagnostics) and the CytoSelect™ 24‑well Cell Migration Assay Kit and the CytoSelect™ 48‑well Cell Adhesion Assay Kit. The expression levels of SFRP4 in uterine leiomyosarcoma tissues were lower than those in normal smooth muscle and uterine fibroid tissues. In addition, SFRP4 suppressed the viability and migration, and increased the adhesion ability of uterine leiomyosarcoma cells compared with in the control group. In conclusion, SFRP4 may suppress the viability and migration, and enhance the adhesion of sarcoma cells. These results suggested that SFRP4 could be considered as a novel therapeutic target for uterine sarcoma.
View Figures
View References

Related Articles

Journal Cover

May-2024
Volume 27 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kagawa T, Mineda A, Nakagawa T, Shinohara A, Arakaki R, Inui H, Noguchi H, Yoshida A, Kinouchi R, Yamamoto Y, Yamamoto Y, et al: New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins. Exp Ther Med 27: 231, 2024.
APA
Kagawa, T., Mineda, A., Nakagawa, T., Shinohara, A., Arakaki, R., Inui, H. ... Iwasa, T. (2024). New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins. Experimental and Therapeutic Medicine, 27, 231. https://doi.org/10.3892/etm.2024.12520
MLA
Kagawa, T., Mineda, A., Nakagawa, T., Shinohara, A., Arakaki, R., Inui, H., Noguchi, H., Yoshida, A., Kinouchi, R., Yamamoto, Y., Yoshida, K., Kaji, T., Nishimura, M., Iwasa, T."New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins". Experimental and Therapeutic Medicine 27.5 (2024): 231.
Chicago
Kagawa, T., Mineda, A., Nakagawa, T., Shinohara, A., Arakaki, R., Inui, H., Noguchi, H., Yoshida, A., Kinouchi, R., Yamamoto, Y., Yoshida, K., Kaji, T., Nishimura, M., Iwasa, T."New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins". Experimental and Therapeutic Medicine 27, no. 5 (2024): 231. https://doi.org/10.3892/etm.2024.12520